Local drug maker forms clinical panel

TAMPA — Intezyne Technologies, a drug development company focused on improving cancer treatment, has formed a clinical panel to help guide the company in designing its clinical studies.

The new Intezyne Clinical Advisory Board includes Dr. David Paul Kelsen of the Memorial Sloan Kettering Cancer Center, Dr. Matthew Kulke of Harvard Medical School, and Dr. David Solit of the Marie-Josee and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering. Kelsen will lead the group.

The organization will offer the company's management guidance and insight into best clinical practices for treating patients with cancer, which will be integrated into the company's clinical study designs.

Amy Lee, PhD, a leading expert in her field, will serve as an adviser/collaborator to the panel.

Intezyne is working to bring its IT-139 to market as a treatment for non-pancreatic neuroendocrine tumors. The compound targets GRP78, a protein that aids in a cancer cell's survival.